Effect of platinum based dual drug second-line therapy on prognosis of NSCLC patients and relative factors analysis
10.3760/cma.j.issn.1673-422X.2018.05.003
- VernacularTitle:铂类为基础的双药二线治疗方案对NSCLC患者预后的影响及其相关因素分析
- Author:
Dazhong WANG
1
Author Information
1. 辽宁省肿瘤医院胸内三科
- Keywords:
Carcinoma,non-small-cell lung;
Drug therapy;
Platinum compounds;
Antineoplastic combined chemotherapy protocols;
Influencing factors
- From:
Journal of International Oncology
2018;45(5):269-272
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the prognostic implications of second-line double drug regimens for advanced non-small cell lung cancer (NSCLC) patients and related factors.Methods Eighty patients with advanced NSCLC who were accepted from January 2014 to December 2016 in our hospital were chosen as the research objects.The patients were randomly divided into two groups using the random number table method,namely single drug group (n =40) and double drug group (n =40).The patients in single drug group were treated with docetaxel or pemetrexed,and the patients in double drug group were treated with docetaxel,pemetrexed,vinorelbine or paclitaxel combined with platinum (cisplatin).The effects of patients in the two groups were compared and the factors affecting the prognosis of the patients were analyzed.Results The remission rate in the double drug group was significantly higher than that in the single drug group (45.0％ vs.20.0％;x2 =4.493,P =0.021).The results of single factor analysis for patients in double drug group showed that pathological type (x2 =7.511,P =0.023),time from first-line treatment to second-line treatment (x2 =6.412,P =0.041),second-line baseline TNM stage (x2 =4.022,P =0.045),second-line cycle number (x2 =5.065,P =0.027),leukopenia (x2 =4.852,P =0.033) and neuron specific enolase (x2 =9.243,P =0.002) were the main prognostic factors of the second-line chemotherapy.The results of multivariate analysis for patients in double drug group showed that time from first-line treatment to second-line treatment (OR =3.511,95 ％ CI:1.486-3.602,P =0.033),second-line baseline TNM stage (OR =1.623,95 ％ CI:1.127-2.119,P =0.027),second-line cycle number (OR =2.208,95 ％ CI:1.589-2.827,P =0.014) and neuron specific enolase (OR =1.960,95％ CI:1.209-2.773,P =0.025) were independent prognostic factors.Conclusion The remission effect of double second-line treatment scheme based on platinum for patients with NSCLC is good,and the time form first-line treatment to second-line treatment,second-line baseline TNM stage,second-line cycle number and neuron specific enolase are independent prognostic factors.
